Details for New Drug Application (NDA): 218515
✉ Email this page to a colleague
NDA 218515 describes PROCHLORPERAZINE MALEATE, which is a drug marketed by Ajanta Pharma Ltd, Amneal, Bionpharma, Chartwell Rx, Duramed Pharms Barr, Glenmark Pharms Ltd, Ivax Sub Teva Pharms, Leading, Norvium Bioscience, Novitium Pharma, Teva Pharms, and Zydus Lifesciences, and is included in fifteen NDAs. It is available from seventeen suppliers. Additional details are available on the PROCHLORPERAZINE MALEATE profile page.
The generic ingredient in PROCHLORPERAZINE MALEATE is prochlorperazine maleate. There are twenty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the prochlorperazine maleate profile page.
The generic ingredient in PROCHLORPERAZINE MALEATE is prochlorperazine maleate. There are twenty-one drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the prochlorperazine maleate profile page.
Summary for 218515
| Tradename: | PROCHLORPERAZINE MALEATE |
| Applicant: | Ajanta Pharma Ltd |
| Ingredient: | prochlorperazine maleate |
| Patents: | 0 |
Suppliers and Packaging for NDA: 218515
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| PROCHLORPERAZINE MALEATE | prochlorperazine maleate | TABLET;ORAL | 218515 | ANDA | Ajanta Pharma USA Inc. | 27241-286 | 27241-286-01 | 100 TABLET in 1 BOTTLE (27241-286-01) |
| PROCHLORPERAZINE MALEATE | prochlorperazine maleate | TABLET;ORAL | 218515 | ANDA | Ajanta Pharma USA Inc. | 27241-287 | 27241-287-01 | 100 TABLET in 1 BOTTLE (27241-287-01) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | May 9, 2024 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | May 9, 2024 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
